Table 2.

Gene region alterations in single CTCs and comparison to tissue biopsy whole-exome sequencing (WES).

CTC sequencing
Number of CTCs detected and single-cell sequenced
Patient ID	mCRPC				NEPC
	Pt 11	Pt 33	Pt 37	Pt 41	Pt 10	Pt 12	Pt 26	Pt 31	Pt 35	Pt 36	Pt 38
Total CTCs	164	12	22	25	113	1365	351	57	38	98	48
CTCs sequenced	16	5	9	7	24	49	25	14	11	16	13
Gene regions evaluated, % of CTCs with gene region alteration
RB1 loss						47	64	14
TP53 loss		33			42	55	8	5	45	31	24
PTEN loss				29				43	45		24
AR gain		83
NCOA2 gain		75	33	43		37		71	27	19
MYC gain	13	83	67	71	38	65	12	79	73	44	38
AURKA gain		42		29		12	8	36			24
UBE2C gain		42				14	8	36			24
DLL3 gain							92	21			15
NCOR1 loss		33			29	6	56	79	18		24
ATM loss							52	14		13
BRCA1 loss		25
BRCA2 loss		25		57			8	5	55	31	4
CDKN1B loss					25	65
CDKN2A loss	13	17		71		6	88	36
ERF loss		17		71		37	8
MAP2K4 loss		33	33		67	12	8	64		19	38
CDH1 loss		5			54			36	82	25	62
TP53/RB1 loss						37	6	14
TP53/PTEN loss								43	27
TP53/PTEN/RB1 loss								14
NCOA2/MYC gain		75	33	43		29		5	27	19
AR/NCOA2 gain		75
Tissue whole exome sequencing (WES)
Tissue WES available	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No
AR	na	AMP							na		na
RB1 loss	na		Deletion			Deletion	Deletion	Deletion	na	Deletion	na
TP53 loss	na		Deletion		Deletion		Deletion	Deletion	na	Deletion	na
PTEN loss	na			Deletion					na	Deletion	na
MYC gain	na		AMP						na	AMP	na
Any BRCA1/BRCA2/ATM	na					Deletion	Deletion	Deletion	na	Deletion	na

Abbreviations. AMP amplification, CTC circulating tumor cell, mCRPC metastatic castration-resistant prostate adenocarcinoma, na not available, NEPC neuroendocrine prostate cancer, Pt patient.